Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

40.49 -0.73 (-1.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
FDA Approves Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults
From Genentech
Via Business Wire
Eli Lilly Expects Enduring Growth, Despite Immediate Challenges
Eli Lilly & Co may be struggling with supply-side issues but new partnerships and a healthy dividend are helping to keep up their momentum 
Via MarketBeat
OTC Market Group’s Most Active List In November: A Dive Into The Names Experiencing Volume Changes
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ)... 
Via TheNewswire.com
Topics ETFs Economy Stocks
Spark Therapeutics Announces Updated Phase 1/2 Study Results Supporting the Durability of Investigational Gene Therapy SPK-8011 in Patients With Hemophilia A
From Spark Therapeutics, Inc.
Via GlobeNewswire
Genentech Presents New Data Demonstrating the Potential of Glofitamab and Mosunetuzumab as Fixed-Duration, Off-The-Shelf Treatment Options for Lymphoma
From Genentech
Via Business Wire
Genentech Presents New and Updated Data for Polivy in Previously Untreated Diffuse Large B-Cell Lymphoma at ASH 2022
From Genentech
Via Business Wire
Interim Data From Phase III Study Presented at ASH 2022 Show Hemlibra (emicizumab-kxwh) Achieved Meaningful Bleed Control in Infants From Birth
From Genentech
Via Business Wire
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
FN Media Group Presents USA News Group News Commentary Vancouver, BC –December 1, 2022 – USA News Group – A series of new Fast Track designations have been handed out by the United States Food and Drug... 
Via FinancialNewsMedia
The OTCQB Venture Market Records 4 Months Of Consecutive Volume Increases In OTC Market Group’s Most-Active List In October
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 8.13% in October — its second-largest monthly increase in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones... 
Via TheNewswire.com
Topics ETFs Stocks
Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies
FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his... 
Via FinancialNewsMedia
Genentech Provides Update on Phase III GRADUATE Program Evaluating Gantenerumab in Early Alzheimer’s Disease
From Genentech
Via Business Wire
Genentech to Present Data at ASH 2022 Showcasing Strength of Hematology Portfolio and Expanding Into New Areas to Address More Patient Needs
From Genentech
Via Business Wire
Most Active On The OTC Markets In September – A Look Back As October Comes To A Close
The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. The Fidelity NASDAQ Composite Index ETF (NASDAQ: ONEQ) and the SPDR Dow Jones Industrial Average... 
Via TheNewswire.com
Topics ETFs Stocks
Positive Topline Phase III Results Show Genentech’s Vabysmo Improved Vision for People Living With Retinal Vein Occlusion (RVO)
From Genentech
Via Business Wire
Early Treatment With Genentech’s Ocrevus (ocrelizumab) Leads to Reduced Disease Progression and Healthcare Costs; Nine-Year Safety Data Reinforce Favorable Benefit-Risk Profile
From Genentech
Via Business Wire
Genentech to Present New Ocrevus (ocrelizumab) Data in Multiple Sclerosis and Continued Research Into Neuromyelitis Optica Spectrum Disorder at ECTRIMS 2022
From Genentech
Via Business Wire
Positive New Data for Genentech’s Evrysdi in Largest Trial Ever Undertaken in Patients With Previously-Treated Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
Good Therapeutics Announces Acquisition of Conditionally Active PD-1-regulated IL-2 Program by Roche
From Good Therapeutics
Via Business Wire
FDA Accepts Supplemental Biologics License Application for Genentech's Polivy Combination for People With Previously Untreated Diffuse Large B-Cell Lymphoma
From Genentech
Via Business Wire
Genentech Announces FDA Approval of Xofluza to Treat Influenza in Children Aged Five and Older
From Genentech
Via Business Wire
Genentech’s Subcutaneous Formulation of Tecentriq Demonstrates Positive Phase III Results
From Genentech
Via Business Wire
Genentech to Present Scientific Progress Across Alzheimer’s Disease Pharmaceutical and Diagnostic Portfolio at 2022 AAIC Annual Meeting
From Genentech
Via Business Wire
New Two-Year Data Confirm Genentech’s Vabysmo Improves Vision With Fewer Treatments for People With Wet Age-Related Macular Degeneration
From Genentech
Via Business Wire
New Data From Phase III HAVEN 6 Study Reinforce Favorable Safety and Efficacy Profile of Genentech’s Hemlibra (emicizumab-kxwh) in People With Moderate or Mild Hemophilia A
From Genentech
Via Business Wire
FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma
From Genentech
Via Business Wire
Genentech Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
From Genentech
Via Business Wire
Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
From Genentech
Via Business Wire
FDA Approves Genentech’s Evrysdi (risdiplam) for Use in Babies Under Two Months With Spinal Muscular Atrophy (SMA)
From Genentech
Via Business Wire
New Pivotal Data Demonstrate Clinical Benefit of Genentech’s Glofitamab, a Potential First-in-Class Bispecific Antibody for People With Aggressive Lymphoma
From Genentech
Via Business Wire
Data at the 2022 ASCO Annual Meeting Highlight Genentech’s Continued Commitment to Innovation in Oncology and Personalized Healthcare
From Genentech
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback